Scientists Figured Out the Indian Cobra’s Genomeat Last – WIRED

In 1891, a French physician named Albert Calmette opened a research outpost in what was then Saigon (now Ho Chi Minh City, Vietnam) to develop new vaccines for rabies and smallpox. Then the Indian cobras showed up.

The invaders sank their fangs into several of Calmettes new neighbors, injecting molecules that rotted muscles, ruptured blood vessels, and paralyzed the nerves that told their hearts to beat and lungs to breathe. Their grisly deaths prompted him to drop infectious disease and focus on snake venom. When he returned to France, he injected Indian cobra venom into rabbits in small doses and discovered that the animals produced a serum with a protective effect: the first antivenom. Calmette began producing his anti-cobra cocktail of antibodies in donkeys and horses and in 1895, for the first time, successfully treated a human snakebite victim.

Calmettes method still dominates antivenom production todaya practically medieval process of snake milking and horse blood harvesting that is laborious, expensive, and error-prone. What scientists have needed in order to modernize this operation is the source code for a snakes noxious protein soup, the actual genes and nearby DNA that turn them on or off.

After two years of work, an international team of scientists has now published, in Nature Genetics, an atlas of all 38 of the Indian cobras chromosomes, the most complete snake genome ever assembled. It contains information no one has ever been able to piece together before: the genetic recipe for the snakes deadly venom cocktail. Theyre hoping it will serve as a roadmap to bring antivenom production into the 21st century.

It seems like something we should have figured out 20 years ago, but until now those areas of the snake genome have been total black boxes, says Todd Castoe, an evolutionary geneticist at the University of Texas at Arlington who was not involved in the work. Initially, scientists believe, the genes that generate venoms carried out totally different functions, usually some innocuous cellular housekeeping task. But along the way they duplicated, a common DNA-copying error. And then the extra copies acquired mutations. That happened over and over, and the proteins they produced became deadly in different ways. The result of all this evolution is that the stretches of DNA that code for venom toxins are full of repetitive sequences, making them exceedingly difficult to properly assemble. Imagine trying to solve a jigsaw puzzle where the same fluffy clouds are scattered six, eight, a dozen times in the same corner of the sky. How do you know which piece goes where?

To finally fit together these elusive sections of the genome, Somasekar Seshagiri, a geneticist and president of the SciGenom Research Foundation in Bangalore, and his collaborators used a combination of older sequencing methods with new ones that read out very long stretches of DNA. They also employed a technique that detects the 3D shape of DNA to further refine their guesses about how exactly to stitch together the structurally finicky venom regions. With the full genome in hand, the researchers then analyzed which sections of it are turned on in the venom gland but not in other tissues. That allowed them to identify the code that spells death or disablement for anyone who encounters the cobras bite.

Antivenoms will no longer just be like some magic potion we pull out of a horse.

Somasekar Seshagiri

Indian cobra venom isnt just one poison; it consists of more than a dozen toxins and other substances that together launch a coordinated attack on the snakes prey (or a hapless human victim). In the Nature Genetics paper, Seshagiris team identified 19 genes key to producing this lethal brew. For the first time, it establishes the links between a snakes toxins and the genes that encode them.

The achievement not only shows scientists how to use the same methods to sequence other venomous snake species, it also unlocks the door to modernizing antivenom production. The value of genomics is that it will allow us to produce medicines that are more concretely defined, says Seshagiri. Antivenoms will no longer just be like some magic potion we pull out of a horse.

See the article here:
Scientists Figured Out the Indian Cobra's Genomeat Last - WIRED

Is ‘No Kill’ Changing the Genetics of Pit Bulls? – City Watch

But a newphenomenon is also developing as a common occurrence -- multiple Pit Bulls attacking as a pack.

Colleen Lynn, founder ofDogsBite.org,which tracks and investigates fatal dog maulings, reports that,of all fatalities,65% involved two or more dogs, a reversal from early CDC (Centers for Disease Control) study years when 70% of fatalities involved a single dog.

Could the number of dogs involved in attacks listed below signal that these expanding policies -- which allow unlimited adoption, ownership, or keeping of Pit Bulls per household be influencing and changing the genetics of Pit Bulls -- and not in a good way?

The following is a single Pit Bull attack that occurred recently.I am providing it to show what was required to stop this dog in an enclosed location with animal-handling experts present.Imagine the terror and damage if there had been more Pit Bulls involved:

Attacking Pit Bull Shot in Animal Shelter to Save Life of Supervisor

Here is a terrifying example of the relentless nature of a Pit Bull attack. It was recorded on the kennel video in the Oakland County animal shelter and reported this week by theDetroit Free Press. The severely injured supervisor was a 25-year veteran of animal care and control.

The four-year-old Pit Bull involved, Roscoe, and had been surrendered after he attacked an adult and two children in the family that had reportedly loved and raised him since a puppy.

"When three Oakland County dog shelter workers couldnt dislodge a ragingpit bull mauling the kennel supervisor, a policeofficer shot thedog in the head, saving the supervisor. . . Yet, the 80-pound dog after being shot at point-blank range, between the eyes, seemingly rose from the dead, the Oakland County spokesman said.

The officer returned to the hallway of the six kennels housing dangerous dogs and found that the pit bull had regained consciousness and "now posed a fresh threat."

The officer saw it was now a wounded animal and the possible threat played through his mind, so he immediately ended its suffering with a second shot that was fatal," the spokesperson said.

The report states that,even after the incident was conveyed to the family, the mother refused to give permission to euthanize the dog, blaming the serious attack on herself and her two children to the fact she had been "talking too loud."

Roscoe had also previously bitten a shelter worker who took him out for a walk.

RECENT ATTACKS BY MULTIPLE PIT BULLS

Three Pit Bulls Kill Womanin Houston, TX on December 21, 2019.DogsBite.orgreports one woman is dead and another severely injured after a vicious dog attack in north Houston, according to police. . .KTRK reports thatall three dogs are pit bulls.

Woman Attacked by 6 Pit Bulls While Walking Dog. . .

Apr 26, 2019 -Awomanis recovering after police say she wasattackedbysix pit bullswhile walking her daughter's dog Wednesday night in Taunton, Massachusetts.. . .The officer then witnessedsix pit bullsfollowing andattacking51-year-old Rochelle Silva.

4 Pit Bulls Attack Woman Walking Dog. . .

Jun 24, 2019 -Awomanwas recovering after she wasattackedbyfour pit bullswhile walking her roommate's dog in Calgary, Canada, on Friday night.

Woman critically injured in Maryland pit bull attack

Nov 14, 2019 -Awomanwas critically injured in anattackby twopit bulls. . .Helicopters were used to searchforthe dog. . .

5 Pit Bulls Attack Woman On Bike, 'Tore Her Apart', Husband. . .

Apr 2, 2019 -A Florida woman underwent surgery Monday after suffering serious injuries following anattackbyfive pit bullson March 28.

Five Pit Bulls Maul Philadelphia Toddler to Death

Aug 2, 2018 -A 2-year-old boy was mauled to death byfive pit bullsat his aunt's house in the Port Richmond area of Philadelphia, local police have said. Officers responding to the incident at around5:35 p.m. Wednesday fired at the dogs to stop theattack, killing one and injuring two others, reported WPVI.

For shocking and informative quick-stats and graphs, see:Deadly Dog Attacks.

Read also:CA Hits Record High in Fatal Dog Attacks in 2019 -- Are Animal ControlPolicies Protecting Us?

HISTORY:PIT BULLSUSED FOR FIGHTING - NOT NANNY DOGS

Human aggression by Pit Bulls was not acceptable in past generations, including by dog fighters.The early 1900's photos which are now purported to be "Nanny Dogs" were actually ads used to show that the breeding stock by a dog man was NOT human aggressive and would not attack a human at a dog fight/match -- it did not mean they were house pets.

Dog fighting was legal in the U.S. at that time and advertising Pits bred for that purpose was rampant. They were bred to attack another dog without provocation andkill quickly and efficiently. They werenotintended to be released into society.(Google 'Pit Bulls for Sale' ads in the early 1900's inDog Fanciermagazine.)

PIT BULLS THAT ATTACK HUMANS NOT KEPT BY DOG FIGHTERS

Following an ad for pups from the line of "Old Family Red Noses and "Red Devils" with photos of "Wilder Red Inferno" and "Mean Girl, " here areexcerptsfrom an op-ed that appears in theAmerican Pit Bull Terrier Gazette(FALL 1997).

SIMPLY RETROSPECT OR RESPECT?(by Charlie Stephens,President, Lone Star APBT Club.)

"LET'S LOOK AT THE 1920'S AND1930'S. Things were very different then.We went to church on Sunday with no thought of burglary or theft, and the dog we had didn't dare bite a human being.If a dog, any dog, was aggressive toward humans it was killed.No, not gassed or injected, it was shot! It was a simple time and that type of dog simply was not tolerated.And this was especially true for the American Pit Bull Terrier. Dogmen of the 1920's and '30's would not allow it!

Today, however, it is different.People are scared, real scared, and they believe they need protection.So, they go out and buy a dog.

(He mentions five incidents of APBT attacks.)

In closing, I make a plea to all dog owners of America. Please take responsibility for your dog. . . If you must own a dog that is human aggressive, then keep it away from humans.And, keep it away from windows too.

PIT BULLS/FIGHTING DOGS CHANGED BY ADAPTATION

AJanuary 18, 2019 article, "The so-called modern bloodlines,"byNeylor Zaurisio, discusses and documents his personal study ofhow, since the 1800's, modern living necessitated adaptations that changed the name of the breed and also affected its size.

"In the late 1800's,with the industrial revolution, thousands of families migrated from rural areas to large industrial centers in search of employment.

Some of these families had as a form of extra income and tradition sold and bet on fighting dogs, Pit Bull dogs. When they saw the opportunity of a better future in the big cities they started to move and took their dogs with them, changing drastically from a habitat where they developed completely, to small spaces in apartments and other cheap options where they were confined most of the time, [loss of] exercise and losing their habit, combined with the selection for smaller dogs, caused a visible reduction in muscular and bone structure.

PIT BULLS HAVE ALSO ADAPTED BY SELECTIVE BREEDING

Pit Bull genetics have been changed several times.In theUnited Kingdom, bull-and-terriers were used inblood sports, such as,bull baitingandbear baitinguntil this was officially eliminated in 1835 when Britain introducedanimal welfare laws.

Sincedog fightingis cheap to organize and far easier to conceal from the law, blood-sport enthusiasts begin to develop dogs that could be pittedagainst each other.

DOG FIGHTERS OPPOSE BSL AND "MANDATORY SPAY/NEUTER"

Dog fighting was used as both a blood sport (usually involving gambling) and a way to continue to test the gameness and maintain fighting blood lines. Maintaining these bloodlines is the reason dog fighters do NOT want "Breed Specific Legislation" (BSL) nor mandatory spay/neuter laws.

If this centuries-old lineage is destroyed, it cannot be replicated.The characteristic of "gameness" means the animals will attack and kill without provocation--includingits own breed.It also means it will continue to fight until it is dead or physically incapable of movement.

PIT BULLS HISTORICALLY KEPT IN ISOLATION

Pit Bulls have traditionally been kept as the only dog in a household, chained or caged in isolation because of their propensity to attack/kill. (Dog fighters keep them caged or "tied out" on chains in their yards.A yard can be any size property, and many keep dozens of dogs -- each far enough from the others to be unable to engage physically. They did not indulge in "play groups."

MULTI-DOG HOUSEHOLDS, NO BSL AND NO PET LIMITS

The "No Kill" movement as prescribed by Best Friends Animal Society has imposed rigid rules for animal shelters and animal owners regardingeuthanizing a dangerous dog, and many veterinarians are afraid to take this risk because of the criticism that can be generated on the Internet.

Prior to this, rules and laws of animal ownership were created and enforced for public and animal health and safety, animals were limited to the number that did not create excessive noise and exhibit behavior issues that decreased or threatened the safety and quality of life of a community.

Best Friends policies links:

Save Them All - Best Friends Animal Society- Best Friends Animal Societyis leading the way.

Best Friends Position Statements on Issues -BestFriendsis opposed tomandatory spayandneuterlaws.

Dog Breed Labels | Best Friends Animal Society-Apr 6, 2018-Labelingshelterdogs as a particularbreedis problematic.Shelterstaff are wrong a majority of the time when identifying a dogs prominent breed. . .

Pet Limit Laws in Los Angeles | The Best Friends Blog

Dec 14, 2010 -Los Angeles is looking to raise itsanimal limit laws. Five reasons whypet limitsare a bad idea in the first place.

Pit Bulls, Dog Breed Discrimination & BSL | Best Friends.

One ofBest Friends' primary goals is to end pit bull breed discrimination,breed-specific legislation(BSL) and the killing of pit bulls in shelters.

Read also:Best Friends Animal Society in Dog Fight over Shock Collars(Nov 25, 2019)

MULTIPLEPIT BULLSMAY BE THE NEXT GATHERING STORM

In 1990, Donald H. Clifford, DVM, and two other noted staff members at the medical College of Ohio, published THE PIT BULL DILEMMA - The Gathering Storm," annotating 1.000 abstracts from books, journals, magazines, newspapers and reports of dog fighting and Pit Bull Attacks.

This was a warning that a new threat was being unleashed on society.(CA enacted a No Breed Specific Legislation prohibition in 1989.)

After Pit Bulls began to be kept as pets, owners generally kept only one orperhaps with a dog of the opposite gender (but even this may not stop them from inevitably fighting or killing each other.)

However, the basic behavior seems to be changing--perhaps as an adaptation to multiple-Pit households--so that numerous Pit Bulls can live together without killing each other but attack as a pack.Is this an anomaly, or is there a change occurring in the genetic structure of the dogs?

IS THE MULTIPLE-PIT BULL ENVIRONMENT CHANGING THE GENETICS OF PIT BULLS?

In the study, "Both Environment and Genetic Makeup Influence Behavior," the following conclusion was reached:

How do genes and the environment come together to shape animal behavior? Both play important roles. Genes capture the evolutionary responses of prior populations to selection on behavior. Environmental flexibility gives animals the opportunity to adjust to changes during their own lifetime.

I am not a geneticist, but I think it is worth questioning whether creating a living environment for Pit Bulls as pets in large or unlimited numbers in the same household is also creating changes in genetics which allows them to act in unison during attacks, but not turn on each other?

And, if so, judging from the recent increase in multiple Pit Bulls attacking as a pack, what issues does this pose for the future of society and community safety?

(Phyllis M. Daugherty is a former City of Los Angeles employee and a contributor to CityWatch.) Edited for CityWatch by Linda Abrams.

See the article here:
Is 'No Kill' Changing the Genetics of Pit Bulls? - City Watch

Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed – Discovery Institute

A new paper in Nature Reviews Genetics, Overcoming challenges and dogmas to understand the functions of pseudogenes, is simply incredible. It documents not only that pseudogenes have been found to have widespread function but also that under current dogma in biology, and given the technical limitations, we are failing to recognize their functions. As Seth W. Cheetham and his co-authors put it, biology suffers from demotivation into exploring pseudogene function by the a priori assumption that they are functionless where The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The abstract lays out exactly what they think:

Pseudogenes are defined as regions of the genome that contain defective copies of genes. They exist across almost all forms of life, and in mammalian genomes are annotated in similar numbers to recognized protein-coding genes. Although often presumed to lack function, growing numbers of pseudogenes are being found to play important biological roles. In consideration of their evolutionary origins and inherent limitations in genome annotation practices, we posit that pseudogenes have been classified on a scientifically unsubstantiated basis. We reflect that a broad misunderstanding of pseudogenes, perpetuated in part by the pejorative inference of the pseudogene label, has led to their frequent dismissal from functional assessment and exclusion from genomic analyses. With the advent of technologies that simplify the study of pseudogenes, we propose that an objective reassessment of these genomic elements will reveal valuable insights into genome function and evolution.

They immediately caution that there are many instances where DNA that was dismissed as pseudogene junk was later found to be functional: with a growing number of instances of pseudogene-annotated regions later found to exhibit biological function, there is an emerging risk that these regions of the genome are prematurely dismissed as pseudogenic and therefore regarded as void of function.

In 2003, Francisco Ayala and Evgeniy Balakirev wrote in Annual Review of Genetics that pseudogenes that have been suitably investigated often exhibit functional roles. This new Nature Reviews Genetics paper offers a very similar statement: Where pseudogenes have been studied directly they are often found to have quantifiable biological roles. Its a long narrative that recounts how many scientists mistakenly dismissed stretches of DNA as pseudogenes. They document dozens of instances where pseudogenes in humans and other organisms have been found to have function.

Some of these functions are protein-based, meaning the pseudogene actually generates a functional protein. But other functions can be RNA-based or DNA-based. For example, most evolutionists would presume that a pseudogene that does not produce a protein cant be functional. But the paper observes that pseudogenes that cannot be translated into a protein may still have a function through their RNA transcript:

Many pseudogenes contain a frequency of mutations that render them unlikely to be (or incapable of being) translated into proteins. However, such mutations do not necessarily preclude pseudogenes from performing a biological function.

The paper notes that even if the RNA transcript of a pseudogene cant be translated into protein, a myriad of RNA-based regulatory mechanisms have been described for pseudogenes, including processing into small interfering RNAs (siRNAs) that may regulate their parent genes, acting as a decoy for transcription factors and, most prominently, as molecular sponges for microRNAs.

Many evolutionists would forcefully assume that if a pseudogene cant even produce an RNA transcript then it cant be functional. But it turns out that pseudogenes that dont produce any RNA transcript (i.e., arent transcribed) can still have important functions:

Another mechanism through which pseudogenes can function is by influencing chromatin or genomic architecture. HBBP1, a pseudogene residing within the haemoglobin locus, enables the dynamic chromatin changes that regulate expression of fetal and adult globin genes during development. Notably, although inhibiting HBBP1 transcription has no effect, deletion of the genomic locus reactivates fetal globin expression. HBBP1 DNA contacts, but not transcription, are required for suppressing the expression of fetal globin genes in adult erythroid cells.

A variety of other non-transcriptional functions are documented in the paper, including stabilizing chromosomes, mediating transcript-splicing, and regulating recombination. Thus, in many cases copy numbers of pseudogenes seem to have functional importance, where deviations from the normal genetic state causes disease. They predict: It is expected that further links between human pseudogene polymorphisms and complex diseases will be identified in the coming years

The implication is that one reason we presume pseudogenes are functionless is because we havent been looking for their functions. And why didnt we look for their functions? Because we presumed they were functionless! So theres a circular aspect to the reasoning here. It has created the science-stopping junk-DNA paradigm, which has prevented us from understanding what pseudogenes really do.

The typical response from evolutionists would be that all of these examples of functional pseudogenes are just isolated rare cases, and that the bulk of pseudogenes are clearly junk. The authors of the paper who give no indication of sympathy for intelligent design, but definitely oppose dismissing pseudogenes as junk are aware of this objection. They say the following in direct rebuttal to it:

The examples of pseudogene function elaborated on here should not imply that pseudogene functionality is likely to be confined to isolated instances. At least 15% of pseudogenes are transcriptionally active across three phyla, many of which are proximal to conserved regulatory regions. It is estimated that at least 63 new human-specific protein-coding genes were formed by retrotransposition since the divergence from other primates. Numerous retrogenes continue to be recognized as functional protein-coding genes rather than pseudogenes across species. High-throughput mass spectrometry and ribosomal profiling approaches have identified hundreds of pseudogenes that are translated into peptides. Although the functions of these peptides remain to be experimentally determined, such examples illustrate the challenge in substantiating a genepseudogene dichotomy.

They continue: As the abundance of such [non-coding-DNA] acquired functions does not appear to be an especially rare or isolated phenomenon, it would seem remiss to take the default perspective that processed pseudogenes are functionless. Instead, it is probable that pseudogene-containing regions of the genome harbour important biological functions that are yet to be revealed.

They point out that current algorithmic and computational methods employed for differentiating pseudogenes and protein-coding genes may overestimate the proportion of the genome that is composed of pseudogenes. Why? Because the properties that are used to define many pseudogenes are also often found in normal protein-coding genes. For example:

Because of this, they argue that computational differentiation of pseudogenes from genes on a purely rule-based system is unlikely to be feasible as it will inherently conflict with many protein-coding genes. They therefore propose markedly softening claims that a stretch of DNA is a pseudogene: it may be useful to consider the annotation of pseudogenes in genomes as a prediction or a hypothesis rather than a classification.

As the authors show, the presumption that a pseudogene is functionless needs to be abandoned. But then, why are we still presuming they are functionless? There are three main reasons: (1) evolutionary thinking has presumed that pseudogenes are functionless junk, (2) terminological dogma reinforces a mindset that pseudogenic regions are intrinsically non-functional, and (3) technological limitations prevent us from discovering their function. The paper acknowledges that problem (3) stems from problem (2), but it fails to explicitly recognize that both problems (2) and (3) ultimately stem from problem (1). In fact it doesnt even identify problem (1) as a problem. Yet the whole situation traces back to bad evolutionary predictions. Lets look at these causes briefly, in reverse order:

The proximal cause that prevents us from understanding pseudogene functions are technological limitations. Because of the junk DNA paradigm, a lot of our biochemical techniques and technologies are set up only to identify standard protein-coding genes. They ignore and dismiss DNA that doesnt fit that mold. Only by updating our technology to detect functional DNA elements that dont necessarily fit the standard definition of a gene can be we begin to understand what pseudogenes really do. The paper explains that technical limitations, informed by our biases and assumptions, demotivate the study of pseudogene functions:

In addition to the demotivation into exploring pseudogene function by the apriori assumption that they are functionless, their systematic study has also been hindered by a lack of robust methodologies capable of distinguishing the biological activities of pseudogenes from the functions of the genes from which they are derived.

They compare the situation to that of long non-coding RNAs (lncRNAs), which were similarly dismissed initially as emanating from junk DNA or as transcriptional noise, largely by virtue of their definition as non-protein-coding. But as technology developed, lncRNAs are now widely recognized as functional and we regularly screen for their functions:

Following a combination of technology developments, genome-wide studies and detailed biochemical studies, lncRNAs are now routinely included in genome-wide analyses, and their functional potential as cellular regulators is widely recognized.

However, at present, the authors note, due in part to the experimental challenge of investigating their function and expression, pseudogenes are typically excluded from genome-wide functional screens and expression analyses. In other words, one of the main reasons we arent finding function for pseudogenes is because we arent looking for it. This needs to change, and they argue that it can.

For example, according to the paper, processed pseudogenes were presumed to have been rendered transcriptionally silent by the loss of cis-regulatory elements. But we now know that thousands of retrotransposed gene copies are transcribed and are often spliced into known protein-coding transcripts and up to 10,000 mouse pseudogenes have evidence of transcription. By trying to study these transcripts we can understand what they may be doing.

One complication is that pseudogene transcription shows cell-type specificity and dynamic expression meaning they may only be transcribed in particular places at particular times. This is all the more reason not to assume that lack of evidence for the function of a pseudogene is evidence that the pseudogene has no function! It very likely may be functional in a cell-type or a situation that we just havent properly investigated yet. As they put it, The use of assays ill-suited to analysis of pseudogenes has arguably stymied elucidation of their biological roles. But they are hopeful: CRISPR-based approaches, carefully applied, have the potential to revolutionize our ability to dissect the functions of pseudogenes. They conclude that its time to stop excluding pseudogenes from biochemical analyses and start using techniques that can identify their functions:

The use of a liberal definition of pseudogenes is attractive as it simplifies genomic analyses. This approach, often unknowingly to the researcher, leads to the consolidation of the pseudogene classification that is, their exclusion by convenience in functional studies. Many regions now considered to be dead genes potentially encode cis-regulatory elements, non-coding RNAs and proteins with impacts in human biology and health. Accordingly, determining the functions of putative pseudogenes warrants active pursuit by their inclusion in functional screens and analyses of genomic, transcriptomic and proteomic data. With innovations in long-read sequencing and CRISPR-based methodologies now readily accessible, the technological limitations that formerly motivated the exclusion from functional investigation are largely resolved.

Until we develop and apply these technologies to put pseudogenes to the proper test, the assumption that they are functionless junk is completely unwarranted. And its not hard to predict what the outcome will be. As Ayala and Balakirev noted, pseudogenes that have been suitably investigated often exhibit functional roles. Or as this new paper observes, Where pseudogenes have been studied directly they are often found to have quantifiable biological roles.

Technology only reflects what people want to do, and there are reasons why biologists have created hardly any technology to investigate pseudogenes: biologists presume (wrongly) that pseudogenes are nonfunctional junk. The paper argues that the terminology associated with the junk DNA paradigm discourages investigation into their function. Thus, we have terms like pseudogene which by their very nature imply that the DNA isnt a gene but something like a wannabe gene that doesnt do anything. As the authors note, the definition of a pseudogene as defective means the non-functionality of pseudogenes remains the dominant and default perception. Citing Thomas Kuhn and his concept of a dominant paradigm that is intolerant of criticisms, they lash the junk-pseudogene paradigm in strong terms:

[T]he term pseudogene itself asserts a paradigm of non-functionality through its taxonomic construction. Pseudogenes are defined as defective and not genes. This point is highlighted because impartial language in science is known to inherently restrict the neutral investigation between conflicting paradigms. In the case of pseudogenes, the term itself is constructed to support the dominant paradigm and therefore limit, consciously or unconsciously, scientific objectivity in their investigation.

Its hard to imagine a greater indictment of the idea that pseudogenes are generally functionless. They continue to explain how use of the term pseudogene hinders scientific research:

Although the pseudogene concept arose to describe an individual molecular phenomenon, the term was rapidly adopted to annotate tens of thousands of genomic regions that met only loosely defined criteria and was effectively axiomatized without being subject to any rigorous scientific debate. This lack of consensus-seeking process has left genome biology with a legacy concept that obscures objective investigation of genome function.

They recommend using different language where [t]he automated classification of gene-like sequences as pseudogenes should be avoided. Instead, we propose that descriptive terms that do not make functional inferences should be used in reference to genomic elements that arose from gene duplication and retrotransposition and terminology should not impose any unsubstantiated assumption on end users.

So what is now stopping us from elucidating the functions of pseudogenes? The only obstacle is a mental block not a technical or evidential one:

The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The paper predicts that as soon as we lose this mindset, there will remain no technical limitations blocking us from progress in understanding the functions of pseudogenes: With renewed scientific objectivity, we anticipate that a wealth of discoveries to understand genome function, its role in disease and the development of new treatments is within reach.

Thats good news, but we must ask a question the paper fails to ask: Why did this terminology develop in the first place?

Evolutionary thinking is the cause that ultimately created, nurtured, and sustained the junk DNA paradigm. Yet the paper adopts a wholly evolutionary approach, and for this reason never identifies evolutionary thinking as the root problem. The closest the authors get is when they recount how the very first paper to identify a pseudogene (published in 1977) dismissed its potential function as a relic of evolution:

In the absence of evidence that the 5S pseudogenes were transcribed, Jacq etal. concluded that the most probable explanation for the existence of the pseudogenes is that they are a relic ofevolution and are functionless1. Since the coining of the term pseudogene, its definition has broadened and is now widely accepted to define any genomic sequence that is similar to another gene and is defective.

This 1977 paper by Jacq et al. was published in the journal Cell and found a pseudogene in an African frog. That paper concluded:

We are thus forced to the conclusion that the most probable explanation for the existence of the pseudogene is that it is a relic of evolution. During the evolution of the 55 DNA of Xenopus laevis, a gene duplication occurred producing the pseudogene. Presumably the pseudogene initially functioned as a 55 gene, but then, by mutation, diverged sufficiently from the gene in its sequence so that it was no longer transcribed into an RNA product.

And there you have it: The pseudogene is seen as a mere a relic produced by mutation until it diverged so much that it was no longer transcribed into an RNA product. This is the classic view of a pseudogene.

Ironically, the 1977 paper went on to speculate that perhaps there is evidence for function for the pseudogene, but the authors privilege the relic view as the right answer until a function can be proven:

This evolutionary explanation for the presence of the pseudogene, however, is incomplete by itself in that it ignores the conservation in sequence of the pseudogene, and indeed of the entire G + C-rich spacer of 55 DNA. In an attempt to explain this, it has been suggested that the pseudogene may be a transcribed spacer corresponding to a primary transcript of 55 RNA, which is a transient precursor and has not so far been detected. If this is so, then most of the G + C-rich region of 55 DNA would be the structural gene for 5S RNA. This function, if true, would provide the necessary selective pressure to conserve the sequence of the linker and pseudogene region so that the correct processing of the postulated 300-long precursor was maintained. In the absence of any experimental evidence for such a long precursor, however, this suggestion must be regarded as speculative; it is more probable that the pseudogene is a relic of evolution.

The recent Nature Reviews Genetics paper hopes to remedy this problem by reviewing much of the overwhelming evidence for pseudogene function and emphasizing how the the non-functionality of pseudogenes remains the dominant and default perception. This will limit, consciously or unconsciously, scientific objectivity in their investigation. The authors are to be commended. However, experience teaches that unless you address the root cause of a problem, it rarely goes away. The tendency to view pseudogenes as a relic of evolution probably wont change as long as you presume that the entire genome is the product of blind evolution. The paper fully endorses the latter view, providing all kinds of narrative gloss that describes pseudogenes (whether functional or not) as retrocopies that arose from gene duplication and transposition. They emphasize:

In the fundamental reductionist approach often assumed in genetics and molecular biology, the perspective is often lost that life as we observe it today is not only the product of billions of years of evolutionary processes but also still subject to these same processes.

They are welcome to take the reductionist approach often assumed in genetics and molecular biology. But until those fundamental evolutionary views of the genome are on the table for questioning, they wont make much progress in shaking the science-stopping assumptions of the junk-DNA paradigm.

Photo: Xenopus laevis, by Brian Gratwicke [CC BY 2.0], via Wikimedia Commons.

More:
Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed - Discovery Institute

‘I would have had another kid’: How an imperfect gene test led to major surgeryand big regrets – The Daily Briefing

When Katy Mathes and six of her family members learned they had a mutation on a BRCA gene that significantly raised their risk of breast cancer they underwent major surgery. But years later, the genetic testing company lowered the family's odds of getting the disease, Amy Dockser Marcus reports for the Wall Street Journal.

In August 2015, Mathes decided to get a BRCA test. Mathes' mother had been diagnosed with breast cancer at 49, and four of her aunts had tested positive for the BRCA gene, and "moved quickly to get surgery," Dockser Marcus reports.

Mathes and her sister, Tricia Leigh, also had positive tests. The test results showed that Mathes had up to an 84% risk of developing breast cancer by age 70 and up to a 27% risk of developing ovarian cancer by age 70. Among the general population, the odds of developing breast or ovarian cancer are 7.3% and 0.7%, respectively, Dockser Marcus reports.

But the two women grappled over the decision of whether to get surgery: Mathes wanted another child and her sister was breastfeeding her second child.

After consulting with additional doctors, Mathes eventually decided to have her ovaries and fallopian tubes removed, the same procedure her aunts, sister, and mother underwent. In addition, Mathes and her sister had double mastectomies.

"I treated my test results like the Bible," Mathes said. "There was no questioning the report."

But years after the initial test, Myriad Genetics, the molecular diagnostics company that did Mathes' test as well as her relatives', changed its classification of the BRCA variant Mathes has from "pathogenic" to "unknown significance," a move that Myriad said is very unusual.

By this point, Mathes and six of her family members had undergone surgery based on their test results. When the sisters learned the news, Mathes said, "My brain just shut off."

Susan Manley, SVP of medical services at Myriad and a board-certified genetic counselor, said, "We know these are very difficult situations. We make these reclassifications very carefully. The science is evolving." She added that changing a classification from harmful to uncertain "is a rare event, but I understand that rare is of no consolation to the patient when it happens to them."

BRCA tests are among the most common genetic tests in existence, Dockser Marcus writes, and genetic testing guidelines have expanded who should receive BRCA tests. Major genetic testing companies such as 23andMe, Ancestry, and MyHeritage now offer the tests for BRCA1 and BRCA2 genes.

However, not every lab agrees on the specific classification of a BRCA gene variant, Dockser Marcus reports. That's in part because there are "tens of thousands of BRCA variants" and not all of them necessarily carry the same level of risk for a patient, Dockser Marcus reports.

Fergus Couch, a professor at the Mayo Clinic, said some variants "have intermediate or moderate levels of risk, not full-blown risk." For a number of those variants, labs "are making a judgment call but that is not always clear to the public," Couch said.

Stephen Chanock, a geneticist at the National Cancer Institute, said, "[G]enetics is murky." He added, "It's not so simple as 'Doctor, do I have to worry or don't I have to worry?'"

According to Melissa Cline, a researcher at the University of California Santa Cruz Genomics Institute, and project manager of the BRCA Exchange, the analysis on the BRCA variant in the Mathes' family put a lot of weight on a 2011 paper that found the variant likely alters the BRCA2 protein, which can help suppress tumors.

Seth Marcus, a genetic counselor at Advocate Health Care who counseled Mathes' mother and one of her aunts, said he checked a public database to see how other labs classify the variant once he heard of Myriad's change. He said six labs still classify the variant as "likely pathogenic."

"In the end, you give the patient the data and the knowledge you know," he said.

Dockser Marcus reports that Myriad currently has 38 people in its database with the BRCA variant Mathes and her relatives have, 12 of whom come from Mathes' family. Mathes said that if she had known about the sample size, she and her husband may have asked more questions about whether surgery was appropriate.

Now, based on Mathes' family history and Myriad's classification change, Mathes' genetic counselor estimated her lifetime risk of developing breast cancer is 21%, Dockser Marcus writes.

"That is not high enough to make me remove organs," Mathes said. "I would have had another kid. I would have waited to do surgery" (Dockser Marcus, Wall Street Journal, 12/20/19).

See the original post here:
'I would have had another kid': How an imperfect gene test led to major surgeryand big regrets - The Daily Briefing

RootPath Raises $11 Million Series A to Accelerate Clinical Translation of its Proprietary Synthetic Immunology Platform – PRNewswire

CAMBRIDGE, Mass., Jan. 6, 2020 /PRNewswire/ --RootPath, a preclinical-stage biotechnology company aiming to enable personalized, highly-potent T cell therapy powered by its proprietary Synthetic Immunology Platform, today announced a $11 million Series A funding round. New investors include Oriza Seed with participation from existing investors Sequoia Capital China, Volcanics Venture, BV (Baidu Ventures) and Nest.Bio Ventures. The company will use the Series A proceeds to validate its tumor-reactive T cell receptor (TCR) discovery workflow, select a lead therapeutic candidate, demonstrate its safety and efficacy in preclinical models and begin IND-enabling development activities.

Launched in 2017 by Nest.Bio Ventures, RootPath has developed a suite of proprietary technologies that comprise its Synthetic Immunology Platform to rapidly and inexpensively recreate T cell immune repertoires and to emulate their antigen-driven selection process in vitro. The Synthetic Immunology Platform centers on the rapid and ultrahigh-throughput generation and functional selection of TCRs, and forms the basis of the personalized T cell therapy that RootPath is advancing. The company had previously announced a $7 M seed round in 2018 led by Sequoia Capital China.

Cell therapies such as chimeric antigen receptor (CAR) therapies have delivered notable successes in hematological malignancies. "The hurdle to achieving effective cell therapies for solid tumors has been identifying safe and effective tumor-reactive agents for these T cells, either as CAR or TCR," said Xi Chen, Ph.D., co-founder and CEO. "Because of the way T cells recognize tumors, discovering tumor-reactive agents for each individual patient or each sub-population of patients has been economically infeasible using existing technologies. This is why we spent the past two years developing our proprietary Synthetic Immunology Platform, which takes advantage of many breakthroughs in synthetic biology and overcomes many intrinsic challenges in immunology-oriented research and drug discovery."

"We are excited to have the support from our new and existing investors to move from technology development to therapeutic translation of our platform," Chen continued.

"Solid tumors are substantially more challenging than hematological malignancies, but, at the same time, represent a more attractive and valuable market," said Grace Yang, Partner of Oriza Seed. "The unique approach RootPath takes effectively creates T cells armed with more targeted weapons, which should translate to increased efficacy and reduced toxicity to patients. We are confident in the Synthetic Immunology Platform, and look forward its clinical translation as well as synergy with potential product candidates from other companies in our existing immuno-oncology portfolio."

About RootPathRootPath is a preclinical-stage biotechnology company pioneering personalized immunotherapy and cell therapy for solid tumors using its proprietary Synthetic Immunology Platform. RootPath was launched by Nest.Bio Ventures in 2017 and has raised $18M in seed and Series A financing. RootPath is located in Cambridge, MA with additional research activities at two sites in China.

SOURCE RootPath

https://www.rootpath.com

Here is the original post:
RootPath Raises $11 Million Series A to Accelerate Clinical Translation of its Proprietary Synthetic Immunology Platform - PRNewswire

Working Together To Drug the Undruggable – Technology Networks

PhoreMost, a UK-based biopharmaceutical company dedicated to drugging undruggable disease targets, has announced that it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, a pharmaceutical company developing therapies for diseases with unsatisfactory treatments. Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones.

PhoreMost will deploy its next-generation phenotypic screening platform, SITESEEKER, towards disease-relevant pathways nominated by Boehringer Ingelheim. Novel targets identified will be further validated and characterized by Boehringer Ingelheim as part of its internal Discovery Research pipeline. Boehringer Ingelheims Research programme is active in the fields of immunology and respiratory diseases, cardiometabolic diseases, oncology research and immuno-oncology, as well as diseases of the central nervous system.

The SITESEEKER platform is based on PhoreMosts core proprietary protein interference, or PROTEINi, technology. Using SITESEEKER, PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. This enables the systematic unmasking of cryptic druggable sites, directly linking them to useful therapeutic functions.

Read the original here:
Working Together To Drug the Undruggable - Technology Networks

RAPT Therapeutics to Present at the 38th Annual JP Morgan Healthcare Conference – BioSpace

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.,(Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., its President and CEO, will present a corporate update and company overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 11:30 a.m. Pacific Time in San Francisco.

A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website athttps://investors.rapt.com/events-and-presentations. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

AboutRAPT Therapeutics, Inc.RAPT Therapeuticsis a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company rapidly develops highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has a diversified portfolio with near-term clinical milestones expected in 2020. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4, for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including general control nonderepressible 2 (GCN2) and hematopoietic progenitor kinase 1 (HPK1), that are in the discovery stage of development.

Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211

Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com

Originally posted here:
RAPT Therapeutics to Present at the 38th Annual JP Morgan Healthcare Conference - BioSpace

Molecular mechanism suggests new ways to bolster immunity to deadly rotavirus: U of T researchers – News@UofT

Researchers at the University of Toronto have discovered how a brief disruption to a molecular pathway in the guts of mice before they are born can compromise immunity in adulthood to a common and often deadly intestinal virus.

The researchers found that in utero inhibition of molecular signalling in the lymphotoxin pathway, long known as important in the development of the immune system, prevented a robust antibody response in adult mice to rotavirus. In humans, rotavirus causes an estimated 215,000 deaths annually, mostly in the developing world.

That early disruption limits the ability of the immune system to later trigger and generate production of Immunoglobulin A (IgA) antibodies, the researchers showed. It also interferes with the nature and function of cells in the gut that support the antibody response, called mesenteric lymph node stromal cells.The research was recently published in the journal Science Immunology.

It was surprising that these non-immune stromal cells were so important to the immune response, saysJennifer Gommerman, a professor ofimmunologyin U of Ts Faculty of Medicine and principal investigator on the study.

It turns out that stromal cells affect the ability of immune B cells to produce IgA that neutralizes rotavirus. Were just beginning to understand the influence these stromal cells can have.

Gommerman says the findings highlight the growing importance of research on the environment in which immune cells function. We typically think of a lymph node as just a bag of lymphocytes, but there is also this supporting structure that clearly has an active role in shaping immunity.

The studys first author, post-doctoral researcherConglei Li, identified a broad subset of stromal cells that affect the immune response to rotavirus. But the key players are likely a subset of that subset, Gommerman says. New technology known as single-cell RNA sequencing should soon enable researchers to identify many more of those cells, she adds.

That work could, in turn, lead to a better understanding of the genetic and environmental factors that may undermine immunity to rotavirus in the developing world, where rotavirus vaccines are much less effective than in high-resource settings.

Gommerman says that while several dysfunctions in the immune system likely contribute to reduced immunity to rotavirus in low-income countries, the current study offers a hint that prevention may be possible.

The thinking would be that if youre pregnant in a resource-depleted area, you may take a dietary supplement at a specific point to ensure proper development of tissues that support immunity, and which enable a vaccine to be more effective, she says.

That kind of intervention is likely a long way off, adds Gommerman, and replicating her results in human pregnancy presents obvious ethical problems. A more immediate next step for her lab is a collaborative study on IgA immune responses to other pathogens such as norovirus, another highly contagious disease.

A focus on single pathogens is useful in studies of IgA, according to Gommerman, because so many factors can influence IgA response. If you simplify the system of study, you get more predictable kinetics and can ask more discrete questions, she says. Weve made a contribution with that approachon a question that has been percolating in several labs for years. That feels good.

The research received support from the Canadian Institutes of Health Research, Princess Margaret Cancer Foundation and the Swiss National Science Foundation.

View original post here:
Molecular mechanism suggests new ways to bolster immunity to deadly rotavirus: U of T researchers - News@UofT

of T, international researchers focus on ‘surprisingly high’ incidence of chronic pain in adolescents – News@UofT

An international research collaboration has been awarded a $9-million research grant from the U.S. National Institutes of Health to tackle the complex problem of chronic musculoskeletal pain in adolescents.

The five-year research project, involving two distinct phases and an international team of researchers from the University of Toronto, the Hospital for Sick Children, Stanford University and Cincinnati Childrens Hospital, will work towards uncovering a biological signature for chronic pain, helping those for whom traditional therapies arent effective.

International in scope and global in its potential impact, the project represents an unprecedented opportunity to perform vital research on a largely unstudied population.

This is the first pediatric study of this magnitude, says project co-investigator Jennifer Stinson, professor in U of Ts Lawrence S. Bloomberg Faculty of Nursing and a nurse practitioner at the chronic pain clinic at the Hospital for Sick Children.

The study will shed light on a phenomenon not well understood. Up to five per cent of adolescents thats 3.5 million in the U.S. alone suffer from chronic musculoskeletal pain. The pain can stem from anything from injuries to juvenile fibromyalgia and Ehlers-Danlos Syndrome, a condition affecting connective tissues in the body.

Childrens chronic pain is really, really underappreciatedin that the incidence of it is surprisingly high, but the awareness of it is surprisingly low, says co-investigator Robert Coghill, director of the Center for Understanding Pediatric Pain and professor of pediatrics at Cincinnati Childrens Hospital Medical Center.

Not all pain is the same, though: A staggering 40 to 60 per cent of sufferers will be considered treatment-resistant. Those adolescents quickly grow into adults with chronic, untreatable pain. But by looking at chronic pain through an array of angles brain imaging, quantitative sensory testing, immunology and psychology the researchers hope to pinpoint which adolescents will or wont respond to treatments, and what underlying factors may be at work in those outcomes.

The first phase of the project will gather these types of data from 250 adolescents aged 14 to 18 who suffer from chronic musculoskeletal pain.

if we are able to capture enough measures across a whole slew of domains, we can then use unbiased machine learning and [big data] algorithms to predict whether patients will respond to treatment or not, explains Massieh Moayedi, assistant professor at U of Ts Faculty of Dentistry, a co-investigator who brings expertise in pain and brain imaging to the project.

A multimodal biomarker will allow us to classify those who are at high risk for pain persistence.

If successful at pinpointing a chronic pain signature, a second phase of the study will commencein which data from a second cohort of 125 adolescent recruits will help validate the pain signature.

This project is really unique, says Stinson, who also leads the iOuch lab at Sick Kids. If we can actually find this biological signature, we have a chance to do more precision medicine based on the phenotype of that child. Well be able to better tailor treatment.

Laura Simons, a psychologist and associate professor at Stanford University with expertise in psychological factors influencing childrens pain, will lead the study.

Im very excited about the immune profiling, says Simons, pointing to a burgeoning field of study that looks at the behaviour of immune cells after trauma or medical interventions such as surgery.

Equally, Simons is curious to see whether some of our pen and pencil measures [of psychology] will rise to the top, to see whether they are as informative as more invasive measures.

While each of the teams will perform their series of tests on their adolescent recruits, Stanford University and the Stanford University Medical Centre will additionally collate data and perform data analysis on the results. The data will remain at Stanford, where the researchers will begin collating one of the worlds largest biobanks of multimodal paediatric pain data for future studies.

Patient recruitment for phase one of the study begins as early as this month.

Go here to see the original:
of T, international researchers focus on 'surprisingly high' incidence of chronic pain in adolescents - News@UofT

Single dose of antibody-based treatment can beat HIV in newborn babies – News-Medical.net

A single dose of an antibody-based treatment can prevent HIV transmission from mother to baby, new nonhuman primate research suggests for the first time. The findings are being published in the journal Nature Communications.

When that single dose is given is key, however. The study found rhesus macaque newborns did not develop the monkey form of HIV, called SHIV, when they received a combination of two antibodies 30 hours after being exposed to the virus.

Delaying treatment until 48 hours, on the other hand, resulted in half of the baby macaques developing SHIV when they were given four smaller doses of the same antibody cocktail. In comparison, the study found macaques that received the current standard HIV treatment - antiretroviral drugs - remained SHIV-free when they started a three-week regimen of that therapy 48 hours after exposure.

These promising findings could mean babies born to HIV-positive mothers can still beat HIV with less treatment."

Nancy Haigwood, Ph.D., study's corresponding's author, professor of pathobiology and immunology in the Oregon Health & Science University School of Medicine, as well as the director at the Oregon National Primate Research Center at OHSU

This is the first time a single dose of broadly neutralizing antibodies given after viral exposure has been found to prevent SHIV infection in nonhuman primate newborns. Previous research by Haigwood, Ann Hessell, Ph.D., and others showed four doses of antibodies started 24 hours after exposure prevented SHIV infection, with all 10 of the baby primates in that study not having any SHIV virus for six months. Both studies used a combination of two antibodies called PGT121 and VRC07-523.

The new study also suggests a much shorter course of antiretroviral therapy given after virus exposure could prevent HIV transmission to newborns. Human babies born from HIV-positive mothers typically take the drug cocktail - a personalized regimen of multiple drugs taken daily - for about six weeks before being re-tested. If the tests are then positive, they likely need to take HIV drugs for the rest of their lives. But this study showed nonhuman primate newborns didn't have SHIV after undergoing antiretroviral therapy for just three weeks starting 48 hours after exposure.

HIV-positive women typically take antiretroviral therapy drugs during pregnancy for their own health, as well as to prevent passing the virus onto their developing child. But mother-to-baby transmission sometimes still happens. Children born to HIV-positive mothers also are given antiretroviral therapy to further prevent infection. However, this drug cocktail can have many negative side effects, involves making special liquid formulations for newborns, and researchers worry about antiretroviral therapy's long-term consequences for development.

Antibodies, however, aren't toxic and can be modified to last a long time in the body, which reduces treatment frequency. This has led researchers to explore their potential to replace or supplement antiretroviral therapy for newborns with HIV-positive mothers as well as for HIV-positive adults.

Next, Haigwood and colleagues plan to see if different antibodies, or a combination of antibodies and antiretroviral therapy, could be even more effective. They also want to determine if the antibodies they evaluate actually eliminate HIV, or only prevent it from replicating.

The research team has regularly shared their primate research findings with the scientific community, including those involved in the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, which is currently leading two trials evaluating a single antibody to treat HIV-exposed newborns.

Source:

Journal reference:

Shapiro, M.B., et al. (2020) Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nature Communications. doi.org/10.1038/s41467-019-13972-y.

See the original post here:
Single dose of antibody-based treatment can beat HIV in newborn babies - News-Medical.net